Our innovative technology will improve the quality of life for people with chronic retinal disease.
Neurotech is a private clinical stage biotech company focused on developing transformative therapies for chronic eye disease.
The core platform technology, Encapsulated Cell Therapy (ECT) enables continuous production of therapeutic proteins to the eye.
THERAPEUTIC AREA OF FOCUS:
RETINA
Macular Telangiectasia (MacTel)
MacTel is a bilateral retinal disease that leads to a gradual loss of central vision. The disease causes photoreceptors to be lost in a well-defined area (Ellipsoid Zone) of the retina. As the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. Our Encapsulated Cell Therapy (ECT) Platform releases Ciliary Neurotrophic Factor (CNTF), a protein shown to protect against the progressive loss of photoreceptors.
There are no known pharmacological treatment options for MacTel today.
All the latest news about Neurotech
,